

TIP60/KAT5 is required for neuronal viability in hippocampal CA1

Inga Urban¹, Cemil Kerimoglu², M. Sadman Sakib², Haifang Wang³, Eva Benito^{2,†}, Christina Thaller¹, Xunlei Zhou^{1,††}, Jun Yan^{3,4}, André Fischer^{2,5,*}, Gregor Eichele^{1,6,*}

¹Genes and Behavior Department, Max Planck Institute for Biophysical Chemistry, 37077 Göttingen, Germany

²Department of Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Göttingen, 37075 Göttingen, Germany

³Institute of Neuroscience, State Key Laboratory of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China

⁴University of Chinese Academy of Sciences, Beijing, China

⁵Department for Psychiatry and Psychotherapy, University Medical Center Göttingen, 37075 Göttingen, Germany

[†]Current address: European Molecular Biology Organization (EMBO), 69117 Heidelberg, Germany

^{††}Current address: Institute of Anatomy and Cell Biology, University of Heidelberg, 69120 Heidelberg, Germany

⁶Lead contact

*Correspondence should be addressed to

Gregor Eichele, Max Planck Institute for Biophysical Chemistry, Am Faßberg 11, 37077 Göttingen, Germany; Tel: +49 551 201-2701; E-Mail: Gregor.Eichele@mpibpc.mpg.de

and

André Fischer, Department of Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Göttingen, Von-Siebold-Str. 3a, 37075 Göttingen, Germany; Tel: +49 551 39-61211; E-Mail: andre.fischer@dzne.de




Figure S1: Gross morphology is unaltered in *Tip60* cKO mice at day 10.

Expression of Neuronal Nuclei (NeuN), Synaptophysin (SYP), Microtubule-associated protein 2 (MAP2) and Glial fibrillary acidic protein (GFAP) in control and *Tip60* cKO hippocampus 10 days after tamoxifen injections. Scale bars: 250 μ m.






Figure S2: Punctate cleaved Caspase 3 and Fractin signal in *Tip60* cKOs at 3 weeks.

(A) Punctate cleaved Caspase 3 (CC3) and Fractin signals (arrowheads) are detectable in the most medial sections (~0.475 mm lateral, Paxinos and Franklin, 2001) of the *Tip60* cKO CA1 region at 3 weeks after tamoxifen injections.

(B) Such signals are absent in controls. Scale bars: 100 μm (A, B, top panels), 50 μm (A, B, middle and bottom panels).

A



B





Figure S3: Fractin-positive neurons and medial-to-lateral spreading of cleaved caspase 3 signal.

(A) Fractin-positive neurons in the CA1 region of a *Tip60* cKO animal at 3 weeks (left) and 2 months (right) after tamoxifen injections.

(B) Activation of Caspase 3 (CC3) in the *TIP60*-deficient hippocampus is restricted to CA1 and progressively spreads more laterally with time. Images of two representative sagittal sections from the same *Tip60* cKO brain at 5 months are shown. Note that CC3 signal is more intense in the more medial section (left) compared to the more lateral section (right) and is restricted to the CA1. Sectioning planes were ~1.4 mm (left) and ~2.2 mm (right) lateral (Paxinos and Franklin, 2001). Scale bars: 50 μ m (A), 250 μ m (B).



B downregulated





Figure S4: Validation of selected genes significantly changed in RNA-Seq analysis.

(A) Validation of selected, differentially expressed genes by qPCR. Comparison of the log₂-transformed fold changes (log₂FC) of RNA-Seq and qPCR shows strong correlation. Data points for downregulated genes are in cyan and for upregulated genes in magenta. The same samples as for RNA-Seq analysis were used (n = 6 per genotype).

(B) Spatial distribution of selected, differentially expressed transcripts in the hippocampus of control and *Tip60* cKO mice analyzed by ISH. Representative images of hippocampal expression of selected genes dysregulated in *Tip60* cKO mice show that for most transcripts differential expression is not restricted to CA1 but covers all hippocampal subregions (cf. expression of *Lin7b*, *Marcks11*, *Syt5*, *Cacng8* and *Esr1*). Note that for *Marcks11* downregulation in DG is even stronger than in CA1 while for *Syt7* it is weaker. Changes of *Syt4* expression in *Tip60* cKO mice depend on the subregion: transcript levels are upregulated in CA1 but downregulated in DG. Cryosections of animals at 10 days after tamoxifen injections were used. n = 4 (*Lin7b*, *Ryr1*, *Esr1*, *Syt4*), n = 3 (*Marcks11*, *Syt5*), n = 1 (*Cacng8*, *Syt7*) per genotype, 4 sections per animal. Scale bars: 250 μm.








Figure S5: H4K12ac levels at dysregulated genes in *Tip60* cKOs and overlap of dysregulated genes with the CK-p25 mouse model.

(A) H4K12 acetylation levels at genes downregulated (left) and upregulated (middle) in *Tip60* cKO mice with p-adjusted < 0.05 and |fold change| > 1.2. Genes downregulated in *Tip60* cKO mice have significantly decreased H4K12ac levels around their TSS (+/- 2000 bp), whereas the upregulated ones do not (right). Moreover, downregulated genes have higher basal levels of H4K12ac compared to upregulated ones. Two-Way ANOVA: Genotype effect (control vs *Tip60* cKO): $p < 0.0001$; Direction effect (downregulated vs upregulated): $p < 0.0001$; Interaction: $p = 0.1019$. Post-hoc multiple comparisons for H4K12ac levels (Sidak's multiple comparison test): downregulated genes: adjusted p-value < 0.001 (***) ; upregulated genes: adjusted p-value = 0.1619.

(B) The overlap between genes downregulated in *Tip60* cKO and those in CK-p25 mice (2 and 6 weeks of induction) (ref³⁶; GSE65159).

(C) The overlap between genes upregulated in *Tip60* cKO and those in CK-p25 mice (2 and 6 weeks of induction) (ref³⁶; GSE65159).

(D) Rank-rank hypergeometric overlap analysis was used between genes dysregulated in *Tip60* cKO and those in CK-p25 mice induced for 6 weeks (ref³⁶; GSE65159). Each pixel represents comparison for one gene color-coded for significance (max $-\log_{10}(p\text{-value}) = 1970$). The most downregulated genes are at the bottom left corner and the most upregulated ones at the upper right corner of the heatmap.

(E) Venn diagrams representing significantly overlapping down- and upregulated genes in *Tip60* cKO and CK-p25 mice (6 weeks induction) (ref³⁶; GSE65159). In each case, the overall significance of the overlaps was determined by permutation tests in which 1000 permutations were performed yielding a highly significant permutation p-value of < 0.0001.






Adownregulated in *Tip60* cKO and CK-p25 2 weeks**B**upregulated in *Tip60* cKO and CK-p25 2 weeks**C**downregulated in *Tip60* cKO and CK-p25 6 weeks**D**upregulated in *Tip60* cKO and CK-p25 6 weeks**E**

Figure S6: GO categories of overlapping genes between *Tip60* cKOs and CK-p25 mice and H4K12ac levels in *Tip60* cKOs at genes dysregulated in CK-p25 mice.

(A, B) GO categories of overlapping downregulated (A) and upregulated (B) genes between *Tip60* cKO mice at 10 days and CK-p25 mice at 2 weeks.

(C, D) GO categories of overlapping downregulated (C) and upregulated (D) genes between *Tip60* cKO mice at 10 days and CK-p25 mice at 6 weeks. 2 weeks after p25 induction represent an early and 6 weeks a late stage of neurodegeneration in CK-p25 mice (ref³⁶).

(E) H4K12 acetylation levels in *Tip60* cKOs and controls at genes downregulated (left) and upregulated (middle) in CK-p25 mice 6 weeks after induction. Genes downregulated in CK-p25 mice have significantly decreased H4K12ac levels around their TS (+/- 2000 bp), whereas upregulated ones do not (right). Moreover, downregulated genes have higher basal levels of H4K12ac than upregulated ones. Two-Way ANOVA: Genotype effect (control vs *Tip60* cKO): $p < 0.0001$; Direction effect (downregulated vs upregulated): $p < 0.0001$; Interaction: $p = 0.0105$. Post-hoc multiple comparisons for H4K12ac levels (Sidak's multiple comparison test): downregulated genes: adjusted p-value < 0.0001 (***); upregulated genes: adjusted p-value = 0.4190.




Figure S7: Behavior.

(A) A *Tip60* cKO animal shows limb claspings at 4 months after tamoxifen injections. No limb claspings are observed in the control animal.

(B) Morris water maze. Average swim speed was comparable between *Tip60* cKO and control animals.

(C) Contextual fear conditioning. *Tip60* cKO and control mice showed comparable freezing behavior during the memory test (ns, $p > 0.05$), $n = 10-12$.

(D) The percentage of time spent in the center of the open field arena was similar between control and *Tip60* cKO mice during a 5 min trial (left). There were no differences in the distance travelled (middle) or the speed (right) between genotypes.

(E) The percentage of time spent in the open arms of the elevated plus maze was significantly higher in *Tip60* cKOs.

Two-tailed student's t-test, ns: $p > 0.05$, * $p < 0.05$, ** $p < 0.01$. Error bars represent SEM. $n = 9-13$ per genotype.

SUPPLEMENTARY METHODS

In situ Hybridization (ISH)

Probes used were:

<i>Lin7b</i>	NM_011698514, nts 12–525, length 514 bp
<i>Esr1</i>	NM_007956, nts 1034–1998, length 964 bp
<i>Cacng8</i>	NM_133190, nts 222–713, 492 bp
<i>Syt7</i>	NM_018801, nts 446–1479, length 1034 bp
<i>Ryr1</i>	NM_009109.1, nts 13752–14519 length 798 bp
<i>Syt4</i>	NM_009308, nts 328–1305, length 977 bp
<i>Marcks11</i>	NM_010807.4, nts 346–1289, length 944 bp
<i>Syt5</i>	NM_016908, nts 35–934, length 899 bp

Quantitative Real-time PCR

Primers used were (5'→3'):

Gap43 forward: AGA TGG TGT CAA GCC GGA AG
Gap43 reverse: CGC CTT TGA GCT TTT TCC TTG T
Syt5 forward: TGG GCC GGA GTT ACA TAG ATA A
Syt5 reverse: GGC CTA GCT GGT GTT TGT CTG
Syt17 forward: GAC ATC AAA CCC GTT GAG TTC G
Syt17 reverse: GTC ATC GGG CGT GTA GGT C
Sst forward: ACC GGG AAA CAG GAA CTG G
Sst reverse: TTG CTG GGT TCG AGT TGG C
Syt9 forward: CTG CCA AGA TTT CAT CTA CCA CC
Syt9 reverse: TCC AAG ACA CGA AAA GAG AGA CA
Sphkap forward: GAG CGG TCC ATG AGT GAA TTA G
Sphkap reverse: CAG AGG CAT GTT CCT TTA TGC T
Sirpa forward: GCT ACC CAC AAC TGG AAT GTC
Sirpa reverse: GGT TAT TTC CCT GGC GTT CTT
Orai1 forward: GAT CGG CCA GAG TTA CTC CG
Orai1 reverse: TGG GTA GTC ATG GTC TGT GTC
Gapdh forward: CAT GGC CTT CCG TGT TCC TA
Gapdh reverse: CCT GCT TCA CCA CCT TCT TGA
Stmn3 forward: CAG CAC CGT ATC TGC CTA CAA
Stmn3 reverse: GTA GAT GGT GTT CGG GTG AGG
Dnm1 forward: AAT ATG CCG AGT TCC TGC ACT
Dnm1 reverse: GTC TCA GCC TCG ATC TCC AG
Stau2 forward: CGA AGG GAG CAG TAT AAA GAA GG
Stau2 reverse: GGT TTG GGA AGC GTA GAT TCA G
Thy1 forward: TGC TCT CAG TCT TGC AGG TG
Thy1 reverse: TGG ATG GAG TTA TCC TTG GTG TT
Ywhah forward: ACG AAG ATC GAA ATC TCC TCT CT
Ywhah reverse: CCG GTA GGC TTT AAC TTT CTC CA
Cdc20 forward: GCC GAA CTC CTG GCA AAT CTA
Cdc20 reverse: TTG GGG GAT AAA GCG GTC AC
Pole forward: CTT TGG AGC GTC GCA ATG G
Pole reverse: ATC TCA GTA GGG TGC ATG TTG AT
Zranb3 forward: GCC ACC TTT CCC ACG AGT AG
Zranb3 reverse: TAG GCA TGG TGA GCC ACA TC
Dtd1 forward: GGC TAG CGT CAC AGT TGG AG
Dtd1 reverse: CTG ACA CAC AGC ACC TCG TA
Mad21 forward: CGA GAC GGT TCG TTT GGT CT
Mad21 reverse: ACC GTC TCT TCA TTG ATG GGG
Adcyap1 forward: CTG CGT GCA GAA ATG CTA CTG
Adcyap1 reverse: AGC CGT AGA GTA ATG GTG GAT AG
Ryr1 forward, reverse: Mm_Ryr1_1_SG QuantiTect Primer (Qiagen)
Egr2 forward, reverse: Mm_Egr2_1_SG QuantiTect Primer (Qiagen)
Esr1 forward, reverse: Mm_Esr1_2_SG QuantiTect Primer (Qiagen)
Crh forward, reverse: Mm_Crh1_1_SG QuantiTect Primer (Qiagen)
Lin7b forward, reverse: Mm_Lin7b_1_SG QuantiTect Primer (Qiagen)

Reln forward, reverse: Mm_Reln_1_SG QuantiTect Primer (Qiagen)